BCDA

BCDA

USD

BioCardia Inc. Common Stock

$1.330-0.080 (-5.674%)

Echtzeitkurs

Healthcare
Biotechnologie
Vereinigte Staaten

Kursdiagramm

Loading Chart...

Schlüsselkennzahlen

Marktkennzahlen
Unternehmensfundamentaldaten
Handelsstatistiken

Marktkennzahlen

Eröffnung

$1.410

Hoch

$1.410

Tief

$1.320

Volumen

0.07M

Unternehmensfundamentaldaten

Marktkapitalisierung

14.1M

Branche

Biotechnologie

Land

United States

Handelsstatistiken

Durchschnittliches Volumen

0.60M

Börse

NCM

Währung

USD

52-Wochen-Spanne

Tief $1Aktuell $1.330Hoch $3.2

Ähnliche Nachrichten

Analyst Upgrades

HC Wainwright & Co. Reiterates Buy on BioCardia, Maintains $25 Price Target

HC Wainwright & Co. analyst Joseph Pantginis reiterates BioCardia with a Buy and maintains $25 price target.

Mehr anzeigen
HC Wainwright & Co. Reiterates Buy on BioCardia, Maintains $25 Price Target
GlobeNewswire

BioCardia Announces Pricing of Up To $12 Million Public Offering

SUNNYVALE, Calif., Sept. 18, 2025 (GLOBE NEWSWIRE) -- BioCardia®, Inc. (NASDAQ:BCDA) ("BioCardia" or the "Company"), a developer of cellular and cell-derived therapeutics for the treatment of cardiovascular and

Mehr anzeigen
BioCardia Announces Pricing of Up To $12 Million Public Offering
GlobeNewswire

BioCardia Announces CardiAMP Chronic Myocardial Ischemia Trial Top Line Data of Roll-in Cohort Show Improved Exercise Tolerance and Reduced Angina Episodes at Six-Month Primary Follow-up

SUNNYVALE, Calif., Sept. 18, 2025 (GLOBE NEWSWIRE) -- BioCardia, Inc. (NASDAQ:BCDA), a developer of cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases, today announced the

Mehr anzeigen
BioCardia Announces CardiAMP Chronic Myocardial Ischemia Trial Top Line Data of Roll-in Cohort Show Improved Exercise Tolerance and Reduced Angina Episodes at Six-Month Primary Follow-up
GlobeNewswire

BioCardia CEO Peter Altman to Present at the H. C. Wainwright 27th Annual Global Investment Conference in New York City September 8-10, 2025

SUNNYVALE, Calif., Sept. 04, 2025 (GLOBE NEWSWIRE) -- - BioCardia®, Inc. (NASDAQ:BCDA), a developer of cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases, today

Mehr anzeigen
BioCardia CEO Peter Altman to Present at the H. C. Wainwright 27th Annual Global Investment Conference in New York City September 8-10, 2025